Hepcidin Levels in Preterm Infants

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2012 by Meir Medical Center.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Meir Medical Center
ClinicalTrials.gov Identifier:
First received: February 21, 2012
Last updated: January 28, 2013
Last verified: November 2012
A recently isolated peptide hormone, hepcidin, is thought to be the principal regulator of iron homeostasis. Hepcidin acts by limiting intestinal iron absorption and promoting iron retention in reticuloendothelial cells. The aims of this study were to determine serum hepcidin levels in preterm infants who receive blood transfusion and preterm infants having sepsis, in order to assess possible relationships between hepcidin and serum iron, serum ferritin,in iron load situations.

Preterm Infants
Anemia of Prematurity
Neonatal Sepsis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Hepcidin Levels in Preterm Infants Receiving Blood Transfusion and During Sepsis.

Resource links provided by NLM:

Further study details as provided by Meir Medical Center:

Primary Outcome Measures:
  • Increase in Hepcidin levels by 30% [ Time Frame: within 24-72 h ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: March 2012
Estimated Study Completion Date: August 2013
Estimated Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
preterm infants

preterm infants receiving blood transfusion

preterm infants with neonatal sepsis.


Ages Eligible for Study:   24 Weeks to 37 Weeks
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Preterm < 38 weeks gestation Need of blood transfusion according to local Protocol. or signs and symptoms of sepsis

Inclusion Criteria:

  • Preterm < 38 weeks gestation
  • Need of blood test for anemia or suspected sepsis

Exclusion Criteria:

  • Major congenital anomalies
  • Birth Asphyxia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01539356

Contact: Shmuel Arnon, MD 972-9-7472225 shmuelar@clalit.oeg.il

Neonatal Intensive Care Unit Recruiting
Kfar-Saba, Israel, 44281
Contact: shmuel arnon, MD       shmuelar@clalit.oeg.il   
Sponsors and Collaborators
Meir Medical Center
  More Information

Responsible Party: Meir Medical Center
ClinicalTrials.gov Identifier: NCT01539356     History of Changes
Other Study ID Numbers: 0154-11-MMC 
Study First Received: February 21, 2012
Last Updated: January 28, 2013
Health Authority: Israel: Ministry of Health

Keywords provided by Meir Medical Center:
Preterm Infants

Additional relevant MeSH terms:
Infant, Premature, Diseases
Anemia, Neonatal
Hematologic Diseases
Infant, Newborn, Diseases
Pathologic Processes
Systemic Inflammatory Response Syndrome
Anti-Infective Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on February 04, 2016